Pub. Date : 2016 Mar 24
PMID : 27011912
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Tacrolimus (Prograf( ), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil, corticosteroids, with or without basiliximab induction. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |
| 2 | Tacrolimus (Prograf( ), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil, corticosteroids, with or without basiliximab induction. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |
| 3 | Tacrolimus (Prograf( ), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil, corticosteroids, with or without basiliximab induction. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |
| 4 | Extended release tacrolimus has similar absorption, distribution, metabolism and excretion to tacrolimus-BID. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |
| 5 | Phase I pharmacokinetic trials comparing extended release tacrolimus and tacrolimus-BID have demonstrated a decreased maximum concentration (Cmax) and delayed time to maximum concentration (tmax) with the extended release formulation; however, AUC0-24 was comparable between formulations. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |
| 6 | Overall extended release tacrolimus has a very similar safety and efficacy profile to tacrolimus-BID. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |